Andrew Kurklinsky, MD
Interventional Cardiology · Tulsa, OKNPI 1831350263
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Medtronic at 24.6% of the total. Reporting peaked in 2019 at $5,188 and has fallen 57.7% since, to $2,196 in 2025.
Across 281 payments — averaging $54.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Penumbra, Inc.$2K
- Boston Scientific$2K
- Terumo Medical Corporation$1K
- Inari Medical, Inc.$1K
- Novartis$663
- plus $4K from 33 others
Across 1 payment — averaging $386.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$387
What the payments were for
- Consulting fees$1,2508%
- Travel & lodging$6,93645%
- Food & beverage$7,08246%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 47 | $3,800 |
| Penumbra, Inc. | 5 | $2,318 |
| Boston Scientific | 25 | $1,640 |
| Terumo Medical Corporation | 4 | $1,479 |
| Inari Medical, Inc. | 8 | $1,346 |
| Novartis | 32 | $663 |
| Abiomed | 12 | $614 |
| Abbott | 10 | $391 |
| Amgen | 18 | $382 |
| AstraZeneca | 20 | $360 |
| Actelion Pharmaceuticals US, Inc. | 4 | $293 |
| E.r. Squibb & Sons, L.L.C. | 16 | $285 |
| Johnson & Johnson | 13 | $231 |
| Biotronik Inc. | 5 | $196 |
| Boehringer Ingelheim | 6 | $191 |
| Edwards Lifesciences | 1 | $161 |
| Merck | 10 | $158 |
| Novo Nordisk | 8 | $157 |
| Angiodynamics, Inc. | 3 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $141 |
| Lexicon Pharmaceuticals, Inc. | 3 | $53 |
| Nuwellis, Inc. | 1 | $47 |
| Bayer | 2 | $44 |
| Philips North America LLC | 2 | $41 |
| Shockwave Medical, Inc | 1 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Pfizer | 2 | $27 |
| Cvrx, Inc. | 1 | $23 |
| Stryker | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Asahi Intecc USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Advisa$2,711
- Indigo System$2,273
- FLOWTRIEVER CATHETER, S$1,270
- CT THROMBECTOMY SYSTEM KIT$1,270
- GENERAL - THERAPIES$1,144
- Navicross$679
- ANGIO-SEAL$450
- Glidesheath$229
- GlideWire$229
- Edora$139
- BioMonitor$139
- Acticor$139
- Solia$139
- Rivacor$139
- MitraClip System$132
- MitraClip$131
- UPTRAVI$129
- OPSUMIT$129
- JARDIANCE$124
- TYRX$117
How this compares
$15,445 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 477 | $419,790 |
| EntrestoSacubitril/Valsartan | 230 | $229,831 |
| XareltoRivaroxaban | 215 | $210,079 |
| FarxigaDapagliflozin Propanediol | 246 | $177,819 |
| JardianceEmpagliflozin | 145 | $149,787 |
| Repatha SureclickEvolocumab | 180 | $111,397 |
| MultaqDronedarone Hcl | 91 | $89,429 |
| VerquvoVericiguat | 93 | $70,955 |
| VascepaIcosapent Ethyl | 111 | $58,744 |
| Praluent PenAlirocumab | 59 | $32,399 |
| BrilintaTicagrelor | 17 | $15,528 |
| Rosuvastatin Calcium | 386 | $15,375 |
| NexlizetBempedoic Acid/Ezetimibe | 22 | $13,952 |
| Atorvastatin Calcium | 436 | $11,685 |
| Ezetimibe | 187 | $10,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $419,790477 claims |
| NovartisEntresto | $663 | $229,831230 claims |
| Johnson & JohnsonXarelto | $231 | $210,079215 claims |
| AstraZenecaFarxiga, Brilinta | $360 | $193,348263 claims |
| Boehringer IngelheimJardiance | $191 | $149,787145 claims |
| Sanofi-aventis U.S. LLCMultaq | $17 | $89,42991 claims |
| MerckVerquvo | $158 | $70,95593 claims |
| Esperion Therapeutics, Inc.Nexlizet | $17 | $13,95222 claims |
| BayerKerendia | $44 | $8,01813 claims |
| AmgenCorlanor | $382 | $7,16613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.